Table 1

Baseline characteristics of the study population

Control (healthy adults)HCMAT-LVH*H-LVH†
N=12N=56N=34N=27p Value‡
Demographics
Age (years)
 Mean±SD29.3±6.354.9±14.928.8±7.247.6±10.6a, c, d, e, f
 Range (minimum–maximum)20–4525–8920–4925–68
Gender (male) %11 (91.7%)29 (49.2%)27 (100%)20 (58.8%)a, c, d, e, f
Height (m)1.73±0.041.7±0.111.99±0.121.74±0.12b, d, e
Weight (kg)76.2±4.580.9±23.9103±11.782.8±25b, d, e
Body surface area (m2)1.9±0.111.98±0.322.4±0.221.9±0.29b, d, e
Blood pressure (mm Hg)
 Systolic119±5133±19133±19149±16a, c ,d, f
 Diastolic75±476±1076±1084±12c, f
Heart rate (bpm)71±1073±1364±1075±9d
QRS duration (ms)101±4105±1596±897±14b, d, f
Corrected QT interval (QTc) ms384±31460±22404±18445±32a, c, d, e
2D echocardiography parameters
LA dimension
 Diameter (cm)3.2±0.44.2±0.63.6±0.43.8±0.5a, c, e
 Indexed for BSA (cm/m2)1.7±0.22.2±0.51.5±0.22±0.4a, c, d, e
LV dimensions
 End-diastolic diameter (cm)4.7±0.54±0.85.3±0.54.1±0.7a, c, d, e, f
 End-systolic diameter (cm)3.1±0.52±0.63.2±0.92.1±0.7a, b, c, d, e
LV fractional shortening (%)34.1±10.450.3±12.539.6±1548.4±11.9a, c, e
LVEF (%)63±265±561±464±5e
Septal wall thickness (mm)8.8±1.423.3±4.911.5±1.116.3±2.3a, b, c, d, e, f
LV posterior wall thickness (mm)8.6±1.415.6±410.5±1.215.2±2.5a, b, c, d, e
Septum-posterior wall ratio1±0.31.5±0.41.1±0.21.1±0.1a, e, f
Relative wall thickness (RWT)0.4±0.10.9±0.40.4±0.10.8±0.3a, c, d, e
Tissue Doppler imaging:
S′ wave (cm/s)6.6±0.84.7±1.26.9±1.35.9±1.3a, e, f
E′ wave (cm/s)9.8±1.53.1±1.710.0±1.75.3±1.7a, c, d, e, f
A′ wave (cm/s)6.6±1.14.9±1.85.9±1.86.4±2.1f
Global thickness dispersion index (ThDI)1.22±0.322.35±0.841.12±0.311.52±0.48a, d, e, f
  • Data are presented as mean±SD.

  • *Professional athletes with physiological left ventricular hypertrophy.

  • †Hypertensive left ventricular hypertrophy.

  • ‡p Values were obtained through Mann-Whitney test or χ2 square as appropriate. a=statistically significant (p<0.05) difference between controls versus HCM; b=statistically significant (p<0.05) difference between controls versus AT-LVH; c=statistically significant (p<0.05) difference between controls versus H-LVH; d=statistically significant (p<0.05) difference between AT-LVH versus H-LVH; e=statistically significant (p<0.05) difference between AT-LVH versus HCM; f=statistically significant (p<0.05) difference between H-LVH versus HCM.

  • AT-LVH, athletes with left ventricular hypertrophy; BSA, body surface area; HCM, hypertrophic cardiomyopathy; H-LVH, hypertensive LVH, LA, left atrium.